Skip to content

Evaluation of Cardiovascular Risks Among the Participants of the EAPC Congress 2026

Cross-Sectional Assessment of Cardiovascular Risk Among EAPC Congress 2026 Participants

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07603869
Acronym
EAPC-CVRISK 20
Enrollment
511
Registered
2026-05-22
Start date
2026-04-23
Completion date
2026-04-24
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risks

Brief summary

The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens. In line with this call for public health diagnosis of CV health, the ESC, through the European Association of Preventive Cardiology (EAPC), is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Preventive Cardiology Congress 2026 from 23-24 April 2026 in Ljubljana, Slovenia. The primary objective of the study is to screen the CV risk among the ESC Annual Congress 2026 attendees with a focus on healthcare professionals (HCP) and to stratify by primary or secondary prevention.

Interventions

BEHAVIORALQuestionnaire and Physical Exam

Questionnaire EQ-5D-5L with some lifestyle habits and medical history

BIOLOGICALblood draw

Blood draw

Sponsors

European Society of Cardiology
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All attendees including healthcare professionals (doctors, nurses, etc.) attending the EAPC Congress 2026 from 23 to 24 April 2026 * Subjects who declare that they are able to understand and give informed consent in English

Exclusion criteria

* Subjects not willing to provide his/her consent to participate in the study. * Subjects who are not suitable candidates for blood extraction.

Design outcomes

Primary

MeasureTime frame
Second Manifestations or Arterial Disease (SMART) risk score in patients with established cardiovascular diseases (CVD) at baselineBaseline
Systemic Coronary Risk Evaluation 2 (SCORE2) score in patients without established CVD at baselineBaseline

Countries

Slovenia

Contacts

STUDY_CHAIRZlatko Fras

Division of Medicine, Centre for Preventive Cardiology, University Medical Centre, Slovenia

STUDY_CHAIRTim Kambič

Department of Medical Sciences in Sport and Exercise, Faculty of Sport, University of Ljubljana, Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026